Estamos no ar no ! Saiba mais

Climb Bio

CLYM

Valor de mercado US$ 564 mi

9,82 USD

-1,09

9,99%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

9,82

0,00

0%

1 dia

-9,99%

5 dias

-9,99%

1 mês

-30,4%

3 meses

-21,94%

6 meses

11,34%

No acumulado do ano

161,87%

1 ano

403,59%

5 anos

-38,39%

10 anos

-38,24%

Sobre: Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Funcionários: 29

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 33,3%

Neutro 44,4%

Negativo 22,2%

Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval

Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug for broader autoimmune indications. CLYM is well-capitalized with $239.2M in cash, providing operational runway into 2H 2028 and enabling progression through key clinical milestones without near-term dilution. CLYM116's modeled quarterly dosing and Budoprutug's CD19 differentiation present compelling product advantages, but both face competitive and execution risks in crowded markets.

Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Investors Business Daily

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.

Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Investors Business Daily

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded

Climb Bio reversed course Thursday despite potential "best-in-class" data for its experimental kidney disease treatment.

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027 Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET WELLESLEY HILLS, Mass.

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Why Is Climb Bio Stock Gaining Friday?

Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets.

Why Is Climb Bio Stock Gaining Friday?

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™